Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04917744 · ClinicalTrials.gov registry record
Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 5
- Enrollment target
NCT04917744: Completed study, sponsored by Mayo Clinic.
NCT04917744 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04917744 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may help researchers better understand the side effects from each treatment and possibly lessen those side effects for future treatments.
Primary Outcome
Levels of MSC-derived cancer support factors will be compared to baseline (i.e. pre-PARPi therapy) at each collection time point by Student's t test. In addition, outcomes by Cox proportional hazards will be compared between designated responders (i.e. patients whose MSC-derived cancer support factors decreased after PARP inhibition) and non-responders (i.e. patients whose MSC-derived cancer support factors did not decrease after PARP inhibition)
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Laboratory Biomarker Analysis
- OTHER Medical Chart Review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2024-02-17 |
What the finished NCT04917744 record still lists
NCT04917744 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT04917744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04917744 about?
NCT04917744 is a clinical study titled "Metabolite Levels in Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors". This study evaluates blood samples and compares levels of metabolites (levels of vitamins, carbohydrates, proteins, etc., that are in the blood), before and after the plasma exchange in patients scheduled to receive immunotherapy for their ovarian cancer. The information gained from this study may h...
What is the current status of trial NCT04917744?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2021-04-01. Estimated completion is 2024-02-17.
What interventions are being tested in trial NCT04917744?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Medical Chart Review (OTHER).
Who is sponsoring clinical trial NCT04917744?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI